What's Going On With Exact Sciences Stock?
Portfolio Pulse from Erica Kollmann
Exact Sciences Corporation (NASDAQ:EXAS) stock is trading higher, with an over 8% gain in the past month. Guggenheim analyst Subbu Nambi initiated coverage with a Buy rating and a $90 price target, while Wolfe Research analyst Doug Schenkel also initiated coverage with an Outperform rating. Exact Sciences presented new data at the 2023 San Antonio Breast Cancer Symposium. The stock is experiencing above-average trading volume, with shares up by 4.2% at $72.33.
December 20, 2023 | 4:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Exact Sciences received Buy and Outperform ratings from Guggenheim and Wolfe Research, respectively, with a price target of $90. The company also presented new data at a major symposium, contributing to a stock price increase and high trading volume.
The positive analyst coverage and the presentation of new data are strong indicators of investor confidence and potential growth, leading to an increase in stock price. The high trading volume further reflects heightened investor interest, which could sustain the upward price movement in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100